# Outcome and Quality of Life of Patients with Severe Chronic Limb Ischaemia: A Cohort Study on the Influence of Diabetes

Ayrton C. Fratezi<sup>1</sup>, Maximiano Albers<sup>1</sup>, Nelson De Luccia<sup>1</sup> and Carlos A. B. Pereira<sup>2</sup>

<sup>1</sup>Department of Surgery, Section of Vascular Surgery, The University of São Paulo School of Medicine and <sup>2</sup> Department of Statistics, Institute for Mathematics and Statistics, The University of São Paulo, Brazil

**Objective:** To determine the influence of diabetes on the use of arterial reconstruction, the rate of amputation and death, and the quality of life of patients with severe limb ischaemia.

Design: A prospective study of patients with the first episode of ischaemia.

Setting: University tertiary referral centre.

*Methods:* Thirty-seven patients with diabetes and 50 without diabetes, were studied over a 12 month period with complete follow-up.

*Main outcome measures:* The proportion of patients undergoing an arterial reconstruction, amputation rate, death rate, and quality-of-life scores.

**Results:** Patients with diabetes underwent an arterial reconstruction less often than patients without diabetes (7/37 vs. 18/50). The odds of patients with diabetes having a higher incidence of adverse outcome was 1666:1 for minor amputation, 26:1 for major amputation, and 4.7:1 for death. There was a tendency towards a lower quality of life for patients with diabetes at 3 (OR 1.94, p = 0.036), 6 (OR 1.58, p = 0.117), and 12 (OR 1.47, p = 0.185) months.

**Conclusions:** In patients with diabetes, (1) the opportunity of undergoing an arterial reconstruction is lower, (2) morbidity and mortality are higher, and (3) the quality of life tends to be worse.

## Introduction

Diabetes mellitus has been associated with a high incidence of adverse outcome in follow-up studies of patients with intermittent claudication.<sup>1,2</sup> Similar investigations of individuals with severe limb ischaemia have been rare,<sup>3,4</sup> probably because a major amputation or an arterial reconstruction is often required. Although diabetes has also been associated with a worse prognosis after a major amputation,<sup>5–7</sup> better or comparable patency rates for infrainguinal bypass grafts have been reported for patients with this disease.<sup>8–12</sup> A possible explanation for this unexpected finding may be that an arterial reconstruction is used less often or more selectively in this group of patients.<sup>3</sup> Therefore, the possibility of a selection bias in surgical decision-making needs to be considered. To reduce bias of this type in studies on prognosis, it is necessary to adopt a prospective strategy, to include individuals before the mode of treatment is selected, and to consider treatments other than arterial reconstruction. In such a study, the outcome measures should include

amputation and death rates but not graft patencies, since the latter are usable only in the subset of patients undergoing arterial reconstruction. In addition, an assessment of quality of life is also important when studying patients with either diabetes<sup>13,14</sup> or arterial occlusive disease.<sup>15,16</sup> For these reasons, we decided to conduct this prospective study on severe limb ischaemia with the principal aim of determining the influence of diabetes mellitus on (1) the use of an arterial reconstruction, (2) the incidence of adverse outcome, and (3) the quality of life.

## **Material and Methods**

## Study design

A cohort design was used to reduce selection bias, evaluate multiple outcomes, determine incidence rates, and assess the quality of life according to a standardised follow-up. The 12 month period of observation was considered adequate to achieve stable results in terms of limb salvage, rehabilitation, quality of life, and cost.<sup>3–5, 16–18</sup> The patients were recruited

Please address all correspondence to: Maximiano Albers, MD Rua Ministro Godói, 1584, apt 74 ZIP 05015-001 São Paulo-Brazil.

consecutively from both the Outpatient Clinics and the Emergency Department of a public university hospital from January 2 to August 31, 1989. Zero time was the date of the first assessment of quality of life, before any treatment was selected.

#### Inclusion criteria

Based on the following criteria, 87 patients were admitted to the study: (1) age of 40 years or more, (2) palpable femoral but absent pedal pulses, (3) presence of rest pain, non-healing ulceration or gangrene, (4) no previous episode of severe ischaemia in either the affected or the contralateral limb, and (5) absence of cancer or mental disorders.

#### Exposure and outcome variables

The exposure variable was diabetes mellitus. A previous diagnosis of diabetes was accepted unless evidence to the contrary was subsequently found. A fasting blood glucose level of 140 mg/100 ml or higher was also a criterion for the diagnosis.

Minor and major amputation and death were the endpoints used in survival analysis. The proportion of patients undergoing an arterial reconstruction and the quality of life were also determined.

## Patients

Fifty patients did not have diabetes mellitus (NDM group), while 37 did (DM group). Of the latter, 36 had type 2 diabetes and one had type 1 diabetes. The prevalence rate of 42% for diabetes was compatible with the findings of two other series at our institution, namely, 38% for 112 infrapopliteal bypasses<sup>19</sup> and 40% for 167 major amputations.<sup>20</sup> The high prevalence of diabetes in this study was probably a result of the referral pattern. On the other hand, only 47 (20 DM, 27 NDM) patients fulfilled the definition of critical leg ischaemia.<sup>21</sup> This corresponds to a prevalence rate of 54% in each group, in agreement with a recently reported rate of 51%.<sup>22</sup> Also of importance, gender, history of smoking, hypertension, and contralateral disease were unequally distributed in both groups (Table 1).

| Table 1. Comparison of the cohorts at baseline |
|--|
|--|

|                       | With diabetes $(n=37)$ | Without diabetes $(n=50)$ |
|-----------------------|------------------------|---------------------------|
| Age (years)           |                        |                           |
| Median                | 69                     | 62                        |
| Interquartile range   | 60-73                  | 54-69                     |
| Men                   | 17                     | 42                        |
| Caucasians            | 30                     | 42                        |
| Smokers               | 14                     | 40                        |
| Hypertension          | 20                     | 12                        |
| Heart disease         | 23                     | 22                        |
| Cerebral ischaemia    | 10                     | 9                         |
| Rest pain only        | 2                      | 8                         |
| Infected lesion       | 20                     | 21                        |
| Critical ischaemia    | 20                     | 27                        |
| Contralateral disease | 26                     | 17                        |
| Serum creatinine      | 13                     | 8                         |
| >1.4 mg/100 ml        |                        |                           |

#### Initial treatment

The initial treatment, that adopted within 60 days of time zero, was classified as conservative, arterial reconstruction or major amputation. The first of these comprised non-surgical treatment: lumbar sympathectomy, debridement, peripheral nerve crushing, and toe or transmetatarsal amputation. Arterial reconstruction consisted of endarterectomy or bypass grafting in the affected limb, whereas major amputation was either below (BK), through (TK) or above (AK) the knee.

## Quality of life

We selected the Spitzer's QL-INDEX<sup>23</sup> which includes five domains of quality of life: (1) Involvement in Own Occupation (Occupation), (2) Activities of The Daily Living (Daily Living), (3) Perception of Own Health (Health), (4) Support of Family and Friends (Support), and (5) Outlook on Life (Outlook). The timeframe for this tool is the week previous to examination and each domain is scored zero, 1 or 2 so that the highest attainable score is 10. Although self-assessment has been recommended,  $^{24-27}$  we did not use this method because of the limitations posed by old age, low literacy and either potential or actual visual loss. In addition, we also considered the advantages of using an interviewer (maximal response rate, no missing items, and minimal errors of misunderstanding).<sup>2</sup> The first author (ACF) assessed all the 87 patients during 321 medical interviews in a 100% complete follow-up. Although not a blinded observer, this author was uninvolved in patient care. The last score of quality of life obtained before death was used at all the subsequent points in time in which a reassessment had been planned, as described by Cox *et al.*<sup>24</sup> (Strategy I). However, a second strategy was also adopted in which only the patients still alive were considered (Strategy II).

## Statistical analyses

The use of an arterial reconstruction was analysed with standard methods for contingency tables. In the survival analysis, exponential survival models were considered using the prior-to-posterior Bayesian operation.<sup>29,30</sup> The posterior survival rates for the two groups were estimated. The probability that the DM group had a failure rate higher than that of the NDM group was evaluated. We represented these posterior probability values by pp-values and called the ratio pp/(1-pp) the Bayes factor. The prior distribution considered here is the uniform non-informative prior. The Mann-Whitney test and the generalised procedure of Morton and Dobson<sup>31</sup> were used for analysing the quality-of-life data. Partitioning of the QL-INDEX into its individual components was performed to show variations in each item. Stratification was undertaken to investigate the confounding effect of gender and history of smoking. Because of a strong association with both hypertension and contralateral disease, the confounding effect of these variables was probably partially corrected. Confidence intervals and p-values were used in the analyses of quality of life, although they have been omitted for convenience in some Tables.

#### Results

#### Use of an arterial reconstruction

Thirty (13 DM, 17 NDM) patients received only

Table 2. Survival analyses for limb and life events

conservative treatment while 25 (7 DM, 18 NDM) patients underwent an arterial reconstruction and the remaining 32 (17 DM, 15 NDM) had a major amputation. Thus, the proportion of patients undergoing arterial reconstruction was 19% for DM and 36% for NDM. Although there was a trend towards lower reconstruction rates in diabetes, this was not statistically significant (Chi square = 2.25, d.f. = 1, 95% CI 4% to 34%, p = 0.133).

#### Survival analyses for limb and life events

There were 60 (29DM, 31 NDM) minor amputations, 43 (21 DM, 22NDM) major amputations, and 13 (7 DM, 6NDM) deaths, corresponding to a relative risk of 2.32, 1.72, and 1.65, respectively. The probability that the failure rate was higher in the DM population of patients with severe limb ischaemia was pp > 0.9994 for minor amputation, pp > 0.9634 for major amputation, and pp > 0.8235 for death. These results are shown in more detail in Table 2.

## Quality of life

The quality of life at baseline was nearly the same in both the cohorts, with an OR of 0.93 (Table 3). With strategy I, the difference in favour of NDM patients was statistically significant at three months (OR) 1.94, p = 0.036), but not at 6 (OR 1.58, p = 0.117) or 12 (OR 1.47, p = 0.185) months. With strategy II, the advantage of NDM patients was smaller and not significant (Table 3).

The breakdown of the global scores of the QL-INDEX into the five primary domains yielded odds ratios higher than 1.00 (Table 4). A comparison of the 12 month quality of life taking into account the ultimate state of the affected limb, showed an

|                     | DM patients ( <i>n</i> =37) |       | NDM patie | ents (n=50) |      |        | Deres fester              |
|---------------------|-----------------------------|-------|-----------|-------------|------|--------|---------------------------|
|                     | Events                      | х     | Events    | Y           | RR   | рр     | Bayes factor<br>pp/(1-pp) |
| A. Loss of the toes | 29                          | 3435  | 31        | 8506        | 2.32 | 0.9994 | 1665.667                  |
| B. Loss of the foot | 21                          | 6115  | 22        | 10995       | 1.72 | 0.9634 | 26.322                    |
| C. Death            | 7                           | 11873 | 6         | 16780       | 1.65 | 0.8235 | 4.666                     |

DM patients (17 men, 20 women).

NDM patients (42 men, 8 women).

X and  $\hat{Y}$  are the total of person-days.

RR is the observed relative risk.

pp refers to the posterior probability.

## A. C. Fratezi et al.

|                 |          | Baseline    |          | 3 mont    | hs      | 6 mon     | 6 months |           | ths    |
|-----------------|----------|-------------|----------|-----------|---------|-----------|----------|-----------|--------|
| Score           | Diabetes | Yes         | No       | Yes       | No      | Yes       | No       | Yes       | No     |
| Deaths          |          | 0           | 0        | 3 (0)     | 3 (0)   | 4 (0)     | 4(0)     | 7(0)      | 6 (0)  |
| 1               |          | 0           | 0        | 1         | 0       | 0         | 0        | 0         | 0      |
| 2               |          | 4           | 9        | 3 (4)     | 5       | 5 (6)     | 2        | 1 (4)     | 2      |
| 3               |          | 12          | 14       | 3 (4)     | 1 (2)   | 1 (2)     | 3 (5)    | 3 (4)     | 4 (6)  |
| 4               |          | 13          | 13       | 13 (14)   | 13 (14) | 9 (11)    | 10 (11)  | 8 (11)    | 8 (10) |
| 5               |          | 6           | 10       | 7`´       | 10 (11) | 4         | 9 (10)   | 3         | 9 (10) |
| 6               |          | 2           | 3        | 6         | 10      | 5         | 4        | 3         | 5      |
| 7               |          | 0           | 1        | 0         | 4       | 4         | 5        | 7         | 4      |
| 8               |          | 0           | 0        | 0         | 2       | 3         | 6        | 5         | 6      |
| 9               |          | 0           | 0        | 0         | 1       | 1         | 3        | 0         | 4      |
| 10              |          | 0           | 0        | 1         | 1       | 1         | 4        | 0         | 2 (3)  |
| Strategy I      |          |             |          |           |         |           |          |           |        |
| Chi squa        | re       | 0.007       |          | 4.394     |         | 2.450     | •        | 1.757     |        |
| <i>p</i> -value |          | 0.933       |          | 0.036     |         | 0.117     |          | 0.185     |        |
| OR              |          | 0.97        |          | 1.94      |         | 1.58      |          | 1.47      |        |
| 95% CI          |          | 0.47 - 1.98 | 5        | 1.04-3.60 |         | 0.892.80  |          | 0.83-2.60 |        |
| Strategy II     |          |             |          |           |         |           |          |           |        |
| Chi squa        | re       | 0.007       |          | 3.632     |         | 1.928     |          | 0.310     |        |
| <i>p</i> -value |          | 0.933       |          | 0.057     |         | 0.16      |          | 0.58      |        |
| OR              |          | 0.97        |          | 1.87      |         | 1.53      |          | 1.19      |        |
| 95% CI          |          | 0.47-1.98   | <b>,</b> | 0.98-3.56 |         | 0.84-2.79 |          | 0.64-2.19 |        |

Table 3. Scores of quality of life at baseline and over a 12 month follow-up under two strategies

Values between parentheses are those used with strategy I.

 Table 4. Breakdown of the QL-INDEX into its five primary domains using scores obtained under strategy I

|                 | Time<br>(months) | Baselin | e   | 3 mont | hs | 6 montl | 18 | 12 mon | ths |
|-----------------|------------------|---------|-----|--------|----|---------|----|--------|-----|
|                 | (                |         |     |        |    |         |    |        |     |
| A. Occupation   |                  |         |     |        |    |         |    |        |     |
| Diabetes        |                  | Yes     | No  | Yes    | No | Yes     | No | Yes    | No  |
| Points          | 0                | 31      | 43  | 31     | 36 | 28      | 31 | 29     | 33  |
|                 | 1                | 6       | 7   | 5      | 11 | 8       | 14 | 8      | 13  |
|                 | 2                | 0       | 0   | 1      | 3  | 1       | 5  | 0      | 4   |
| OR              |                  | 0       | .84 | 1.     | 98 | 1.      | 95 | 1      | .99 |
| B. Daily living |                  |         |     |        |    |         |    |        |     |
| Diabetes        |                  | Yes     | No  | Yes    | No | Yes     | No | Yes    | No  |
| Points          | 0                | 21      | 25  | 20     | 19 | 18      | 18 | 17     | 18  |
|                 | 1                | 16      | 24  | 16     | 26 | 16      | 21 | 20     | 22  |
|                 | 2                | 0       | 1   | 1      | 5  | 3       | 11 | 0      | 10  |
| OR              |                  | -       | .35 | 2.0    | 00 | 1.      | 86 | 2      | .07 |
| C. Health       |                  |         |     |        |    |         |    |        |     |
| Diabetes        |                  | Yes     | No  | Yes    | No | Yes     | No | Yes    | No  |
| Points          | 0                | 16      | 17  | 7      | 6  | 6       | 4  | 6      | 3   |
|                 | 1                | 20      | 33  | 27     | 36 | 17      | 28 | 16     | 28  |
|                 | $\overline{2}$   | 1       | 0   | -3     | 8  | 14      | 18 | 15     | 19  |
| OR              |                  | - 1     | .35 | 1.     | 82 | 1.      | 13 | 1      | .14 |
| D. Support      |                  |         |     |        |    |         |    |        |     |
| Diabetes        |                  | Yes     | No  | Yes    | No | Yes     | No | Yes    | No  |
| Points          | 0                | 1       | 1   |        | 0  | 2       | 0  | 2      | 0   |
|                 | 1                | 5       | 10  | 2      | 4  | 1       | 1  | 1      | 1   |
|                 | 2                | 31      | 39  | 34     | 46 | 34      | 49 | 34     | 49  |
| OR              |                  |         | .70 | 1.0    |    |         | 38 |        | .38 |
| E. Outlook      |                  |         |     |        |    |         |    |        |     |
| Diabetes        |                  | Yes     | No  | Yes    | No | Yes     | No | Yes    | No  |
| Points          | 0                | 10      | 17  | 8      | 5  | 7       | 4  | 7      | 5   |
|                 | 1                | 27      | 33  | 27     | 41 | 25      | 35 | 20     | 28  |
|                 | 2                | 0       | 0   | 2      | 4  | 5       | 11 | 10     | 17  |
| OR              | -                |         | .72 | ~ 2.0  |    | 2.02    |    | 1.52   |     |

None of the differences were statistically significant.

Eur J Vasc Endovasc Surg Vol 10, November 1995

|                 | No major<br>amputation |            | BK or TK<br>amputation |           | AK amputation |       |
|-----------------|------------------------|------------|------------------------|-----------|---------------|-------|
| Score Diabetes  | Yes                    | No         | Yes                    | No        | Yes           | No    |
| Deaths          | 6                      | 3          | 0                      | 2         | 1             | 1     |
| 2               | 0 (2)                  | 0          | 0                      | 2         | 2             | 0     |
| 3               | 0(1)                   | 1 (2)      | 2                      | 3         | 1             | 0 (1) |
| 4               | 1 (4)                  | 1          | 3                      | 4 (6)     | 4             | 3     |
| 5               | 1                      | 6 (7)      | 2                      | 3         | 0             | 0     |
| 6               | 2                      | 3          | 1                      | 2         | 0             | 0     |
| 7               | 4                      | 3          | 3                      | 1         | 0             | 0     |
| 8               | 5                      | 6          | 0                      | 0         | 0             | 0     |
| 9               | 0                      | 4          | 0                      | 0         | 0             | 0     |
| 10              | 0                      | 2 (3)      | 0                      | 0         | 0             | 0     |
| Strategy I      |                        |            |                        |           |               |       |
| Chi square      | 3                      | .058       |                        | 1.694     | (             | ).594 |
| <i>p</i> -value | 0                      | .080       | 0.193                  |           | 0.441         |       |
| OR              | 2                      | .01        | 0.47                   |           | 2.75          |       |
| 95% CI          | 0                      | .92-4.39   | 0.15-1.46              |           | 0.21 - 36.02  |       |
| Strategy II     |                        |            |                        |           |               |       |
| Chi square      | 0                      | .067       | 1.481                  |           | 1.125         |       |
| p-value         | 0                      | .796       | (                      | 0.223     | 0.289         |       |
| ÔR              | 1                      | .13        | 1                      | 0.49      | -             |       |
| 95% CI          | 0                      | .45 - 2.80 | I                      | 0.16-1.54 | -             |       |

 Table 5. Twelve-month quality of life according to the ultimate state of the limb

Values between parentheses are those used with strategy I.

increased risk for DM persons in both the subgroup with no major amputation (19 DM, 29 NDM) and the subgroup with an AK amputation (7 DM, 4 NDM), but not in that with a BK amputation (11 DM, 17 NDM), as shown in Table 5.

Stratification by gender and history of smoking revealed that the increased risk for both a minor amputation and a worse quality of life in DM patients was unconfounded. However, there were variations in risk in opposite directions for both major amputation and death (Table 6).

 Table 6. Stratified analysis of minor and major amputation, death, and quality of life

|                                |        | Men       | Women  |           |  |
|--------------------------------|--------|-----------|--------|-----------|--|
|                                | Smoker | Nonsmoker | Smoker | Nonsmoker |  |
| A. Minor<br>amputation         | 1.61   | 2.77      | 5.23   | 1.87      |  |
| B. Major<br>amputation         | 0.78   | 1.97      | •••    | 0.75      |  |
| C. Death<br>D. Quality of life | 3.37   | 3.96      | •••    | 0.15      |  |
| Baseline                       | 0.85   | 1.00      | 0.83   | 1.71      |  |
| 3 months                       | 3.38   | 1.37      | 8.00   | 1.27      |  |
| 6 months                       | 1.20   | 2.13      | 7.40   | 2.50      |  |
| 12 months                      | 0.75   | 4.00      | 2.00   | 2.83      |  |

Values are stratum-specific relative risks (A, B and C) or odds ratios (D).

## Discussion

The results of this study indicate that DM patients undergo arterial reconstruction less often than NDM patients, with a difference of 17% and a relative decrease of 47%. An even greater difference of 29% (14% DM, 43% NDM) has been reported by others.<sup>3</sup> These differences are large enough to suggest that arterial reconstruction is considered with more care in DM patients than it is in NDM patients. If this is so, a selection bias is introduced in studies comparing the results of arterial reconstruction in these groups. For this reason, the possibility of a selection bias must be seriously considered before accepting the better or comparable results for DM patients in some series of infrainguinal reconstruction.<sup>8–12</sup> Indeed, certain sources of bias in these studies are readily apparent as is the case for demographic variables,<sup>12</sup> surgical indication,<sup>12</sup> type of bypass,<sup>9,10</sup> and distal anastomosis sites.<sup>8,10–12</sup> Other problems include confounding by the use of tobacco<sup>10</sup> and undue confidence in subgroup analysis.8,10

Under the Bayesian rationale, we believe that the probability of a minor amputation in the population of DM patients far exceeds that of the NDM population (Bayes factor 1666:1). Such a striking difference between DM and NDM patients would hardly be a result of confounding, as confirmed by a stratumspecific odds ratio ranging from 1.61 to 5.23 (Table 6). The difference was less impressive for a major amputation (Bayes factor 26:1). Consistent with this interpretation, the relative risk was lower than 1.00 in two strata (Table 6). This is an indication of confounding. However, a worse prognosis for the limb in DM patients has been widely reported.<sup>1,3-7,32,33</sup> Although the present study was too short in duration to confidently assess death rates, we found a slightly increased risk for DM patients, as expected.<sup>3,5</sup> Chance is the best explanation for the disparities found with stratification for this latter variable (Table 6).

The quality of life scores were higher for NDM patients in all three assessments made during the follow-up. The stratum-specific odds ratios greater than 1.00 in 11 out of 12 follow-up measures indicate absence of confounding. Although difficult to ascertain on clinical grounds, some supportive evidence in favour of the relevance of the differences in quality of life was provided by the partitioning of the QL-INDEX scores. This showed that all the five domains were scored higher in NDM patients, with no change in opposite direction that could mislead the summed scores.<sup>24</sup> In our opinion, this result is an indication of the strengths of the QL-INDEX in the setting of limb

ischaemia. With regard to the individual domains, the high number of patients scoring zero for occupation is in agreement with the idea that it should be replaced by Mobility in order to improve the QL-INDEX.<sup>34,35</sup> The insensitivity to change identified for Support<sup>34</sup> was also confirmed. On the contrary, the readily apparent improvement with time for Daily Living, Health and Outlook reflects a good sensitivity to change (Table 4).

As expected, quality of life scores were the highest for patients who did not have a major amputation, intermediate for those with either a BK or a TK amputation, and lowest in the subgroup having an AK amputation. These differences are a further indication of the adequacy of the QL-INDEX as an outcome measure in this study. Although a better quality of life was found for DM patients with a BK or a TK amputation, this was probably a result of small subgroup sizes.

The probabilities under the rationale of Bayesian inference support our believe that adverse outcomes are more frequent in DM patients. In addition, the difference in quality of life according to the usual frequentist principles was also less favourable to these patients. Our conclusions are that in DM patients: (1) the opportunity of undergoing an arterial reconstruction is lower, (2) morbidity and mortality are higher, and (3) the quality of life tends to be worse.

#### References

- 1 HUGHSON WG, MANN JI, TIBBS DJ, WOODS HF, WALTON I. Intermittent claudication: Factors determining outcome. *Br Med* J 1978; 1: 1377–1379.
- 2 BRAND FN, ABBOTT RD, KANNEL WB. Diabetes, intermittent claudication, and risk of cardiovascular events. The Framingham Study. *Diabetes* 1989; 38: 504–509.
- 3 STEER HW, CUCKLE HS, FRANKLIN PM, MORRIS PJ. The influence of diabetes mellitus upon peripheral vascular disease. *Surg Gynecol Obstet* 1983; 157: 64–72.
- 4 WOLFE JHN. Defining the outcome of critical ischaemia: a one year prospective study. Br J Surg 1986; 73: 321.
- 5 DE LUCCIA N, PINTO MAGS, GUEDES JPB, ALBERS MTV. Rehabilitation after amputation for vascular disease: a follow-up study. *Prosthet Orthotics Int* 1992; 16: 124–128.
- 6 CRISTENSEN KS, FALSTIE-JENSEN N, CHRISTENSEN ES, BROCHNER-MORTENSEN J. Results of amputation for gangrene in diabetic and non-diabetic patients. J Bone Joint Surg 1988; 70A: 1514–1519.
- 7 HOSIE KB, KOCKELBERG R, NEWBURY-ECOB RA, CALLUM KG, NASH JR. A retrospective review of the outcome of patients over 70 years of age considered for vascular reconstruction in a District General Hospital. *Eur J Vasc Surg.* 1990; 4: 313–315.
- 8 TAYLOR Jr LM, EDWARDS JE, PORTER JM. Present status of reversed vein bypass grafting: five-year results of a modern series. J Vasc Surg 1990; 11: 193–206.

- 9 HURLEY JJ, AUER AI, HERSHEY FB *et al.* Distal arterial reconstruction: patency and limb salvage in diabetics. *J Vasc Surg* 1987; 5: 796–802.
- 10 RUTHERFORD RB, JONES DN, BERGENTZ SE *et al.* Factors affecting the patency of infrainguinal bypass. *J Vasc Surg* 1988; 8: 236–246.
- 11 ROSENBLATT MS, QUIST WC, SIDAWY AN, PANISZYN CC, LOGERFO FW. Results of vein graft reconstruction of the lower extremity in diabetic and nondiabetic patients. *Surg Gynecol Obstet* 1990; **171**: 331–335.
- 12 SHAH DM, CHANG BB, FITZGERALD KM, KAUFMAN JL, LEATHER RP. Durability of the tibial artery bypass in diabetic patients. *Am J Surg* 1988; **156**: 133–135.
- 13 GAFVELS C, BORJESSON B, LITHNER F. The social consequences of insulin-treated diabetes mellitus in patients 20-50 years of age. An epidemiological case-control study. *Scand J Soc Med* 1991; 19: 86–93.
- 14 HANESTAD BR, HORNQUIST JO, ALBREKTSEN G. Self-assessed quality of life and metabolic control in persons with insulindependent diabetes mellitus (IDDM). *Scand J Soc Med* 1991; **19**: 57–65.
- 15 SCHNEIDER JR, MCHORNEY CA, WARE JA *et al*. Functional health in patients with severe peripheral vascular occlusive disease. *Ann Vasc Surg* 1993; 7: 419–428.
- 16 ALBERS M, FRATEZI AC, DE LUCCIA N. Assessment of quality of life of patients with severe ischaemia as a result of infrainguinal arterial occlusive disease. J Vasc Surg 1992; 16: 54–59.
- 17 MACKEY WC, MCCULLOUGH JL, CONLON TP et al. The costs of surgery for limb-threatening ischaemia. Surgery 1986; 99: 26–35.
- 18 TROËNG T, BERGQVIST D, JANSON L. Incidence and causes of adverse outcomes of operation for chronic ischaemia of the leg. *Eur J Surg* 1994; 160: 17–25.
- 19 ALBERS M, DE LUCCIA N, AUN R, PRESTI. Long-term comparison of in situ and non-reversed saphenous vein grafts for infrapopliteal reconstruction. *Vasc Surg* (in press).
- 20 DE LUCCIA N, ALBERS MTV, TOZZI FL et al. Amputação do membro inferior por doença arterial periférica: análise de 167 casos consecutivos não selectionados. *Rev Bras Ortop* 1989; 24: 296–300.
- 21 Second European Consensus Document on Chronic Critical Limb Ischaemia. Eur J Vasc Surg 1992; 6(Suppl A): 1–32.
- 22 THOMPSON MM, SAYERS RD, VARTY K, REID A, LONDON NJM, BELL PRF. Chronic critical leg ischaemia must be redefined. *Eur J Vasc* Surg 1993; 7: 420–426.
- 23 SPITZER WO, DOBSON AJ, HALL AJ *et al*. Measuring the quality of life of cancer patients: a concise QL-INDEX for use by physicians. *J Chron Dis* 1981; **34**: 585–597.
- 24 COX DR, FITZPATRICK R, GORE SM, SPIEGELHALTER DJ, FLETCHER AE, JONES DR. Quality of life assessment: can we keep it simple? J Royal Stat Soc (Ser. A) 1992;155: 353–392.
- 25 GUYATT GH, VAN ZANTEN SJOV, FEENY DH, PATRICK DL. Measuring quality of life in clinical trials. *Can Med Ass J* 1989; 140: 1441–1448.
- 26 SLEVIN ML, LYNCH D, DRINKWATER J, GREGORY WM. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988; 57: 109–112.
- 27 FRASER SCA. Quality-of-life measurement in surgical practice. Br J Surg 1993; 80: 163–169.
- 28 GUYATT GH, FEENY DH, PATRICK DL. Measuring health-related quality of life. Ann Intern Med 1993; 118: 622–629.
- 29 AITCHISON J, DUNSMORE IR. Statistical prediction analysis. Cambridge: Cambridge University Press, 1975.
- 30 KALBFLEISCH JD, PRENTICE RL. The statistical analysis of failure data. New York: John Wiley, 1980.
- 31 MORTON AP, DOBSON AJ. Analysing ordered categorical data from two independent samples. *Br Med J* 1990;301: 971–973.
- 32 DUNCAN HJ, FARIS IB. Skin vascular resistance and skin perfusion pressure as predictors of healing of ischaemic lesion of the lower limb: influence of diabetes mellitus, hypertension, and age. *Surgery* 1986; **99**: 432–438.

Eur J Vasc Endovasc Surg Vol 10, November 1995

- 33 COHEN DL, NEIL HA, THOROGOOD M, MANN JI. A populationbased study of the incidence of complications associated to type 2 diabetes in the elderly. *Diabetic Med* 1991; 8: 928–933.
- 34 MORRIS JN, SUISSA S, SHERWOOD S, WRIGHT SM, GREER D. Last days: a study of the quality of life of terminally ill cancer patients. J Chron Dis 1986; 39: 47–62.
- 35 PELL JP, DONNAN PT, FOWKES FGR, RUCKLEY CV. Quality of life following lower limb amputation for peripheral arterial disease. *Eur J Vasc Surg* 1993; 7: 448–451.

Accepted 22 February 1995